Know Cancer

forgot password

17 Years
40 Years
Open (Enrolling)
Polycystic Ovary Syndrome

Thank you

Trial Information

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive
age with a probable prevalence of 5% to 10%. PCOS is characterized by chronic anovulation,
menstrual irregularities, evidence of hyperandrogenism (either clinical, manifested as
hirsutism, acne, male pattern balding, or biochemical, manifested by elevated serum adrenal
and/or ovarian androgen concentration). Fifty percent of all patients with PCOS are obese,
and the presence of obesity affects the clinical manifestations of PCOS. The underlying
pathogenic mechanisms appear to involve insulin resistance and hyperinsulinemia, the
magnitude of which is greater in obese than in non-obese women with PCOS.

Inclusion Criteria:

- 1. Oligomenorrhea ( less than 6 times spontaneous MC per year) or Amenorrhea. 2.
Hyperandrogenism (either clinical or biochemistry. 3. PCO by ultrasound. 4.After
menarche, before menopause.

Exclusion Criteria:

- 1. hormone therapy in the past 6 months. 2. Pregnancy in the past 6 months 3.Acute
illness found in the past 3 months. 4.Systemic disease including autoimmune disease,
malignancy, hepatic, renal or CVS disease, and ever received chemotherapy or
immunosuppressive agents.

Type of Study:


Study Design:

Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Cross-Sectional, Time Perspective: Prospective

Principal Investigator

Horng-Nerng Ho, M.D.

Investigator Role:

Study Director

Investigator Affiliation:



Taiwan: Department of Health

Study ID:




Start Date:

October 2004

Completion Date:

August 2005

Related Keywords:

  • Polycystic Ovary Syndrome
  • Polycystic Ovary Syndrome